NovoCure Limited Company Profile (NASDAQ:NVCR)

About NovoCure Limited (NASDAQ:NVCR)

NovoCure Limited logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVCR
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.88241 billion
  • Outstanding Shares: 89,003,000
Average Prices:
  • 50 Day Moving Avg: $19.72
  • 200 Day Moving Avg: $14.71
  • 52 Week Range: $5.95 - $22.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -50.12
  • P/E Growth: -0.47
Sales & Book Value:
  • Annual Revenue: $125.17 million
  • Price / Sales: 14.97
  • Book Value: $1.33 per share
  • Price / Book: 15.83
  • EBIDTA: ($69,140,000.00)
  • Net Margins: -75.91%
  • Return on Equity: -69.48%
  • Return on Assets: -34.71%
  • Debt-to-Equity Ratio: 0.82%
  • Current Ratio: 6.72%
  • Quick Ratio: 6.01%
  • Average Volume: 976,283 shs.
  • Beta: 4.42
  • Short Ratio: 5.89

Frequently Asked Questions for NovoCure Limited (NASDAQ:NVCR)

What is NovoCure Limited's stock symbol?

NovoCure Limited trades on the NASDAQ under the ticker symbol "NVCR."

How were NovoCure Limited's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, July, 27th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.01. The company earned $38.38 million during the quarter, compared to analyst estimates of $42.20 million. NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. View NovoCure Limited's Earnings History.

When will NovoCure Limited make its next earnings announcement?

NovoCure Limited is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for NovoCure Limited.

Where is NovoCure Limited's stock going? Where will NovoCure Limited's stock price be in 2017?

7 equities research analysts have issued 12-month price targets for NovoCure Limited's stock. Their forecasts range from $14.00 to $34.00. On average, they anticipate NovoCure Limited's share price to reach $20.14 in the next year. View Analyst Ratings for NovoCure Limited.

What are analysts saying about NovoCure Limited stock?

Here are some recent quotes from research analysts about NovoCure Limited stock:

  • 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (8/1/2017)
  • 2. J P Morgan Chase & Co analysts commented, "NVCR’s 1Q report (slides here) was largely uneventful as the co continues to make progress with the Optune launch. 1Q net revenues were $35M vs. consensus of $41M (though we note the cash vs. accrual accounting makes net revenue hard to predict). There were 1,266 active patients on therapy at 1Q-end (+16% q/q), ahead of our 1,226 estimate. We are encouraged by the progress here, though will be looking for momentum to continue to build following recent reimbursement wins, NCCN guidelines, as well as impressive follow-up survival data from the pivotal EF-14 trial." (5/1/2017)

Who are some of NovoCure Limited's key competitors?

Who are NovoCure Limited's key executives?

NovoCure Limited's management team includes the folowing people:

  • William F. Doyle, Executive Chairman of the Board
  • Asaf Danziger, Chief Executive Officer, Director
  • Kinyip Gabriel Leung, Vice Chairman of the Board
  • Yoram Palti M.D., Ph.D., Founder, Director
  • Wilhelmus C. M. Groenhuysen, Chief Financial Officer
  • Michael J. Ambrogi, Chief Operating Officer
  • Eilon D. Kirson M.D., Ph.D., Chief Science Officer and Head of Research and Development
  • Todd Longsworth, General Counsel
  • William T. Burkoth, Independent Director
  • Louis J. Lavigne Jr., Independent Director

Who owns NovoCure Limited stock?

NovoCure Limited's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (7.74%), Goldman Sachs Group Inc. (5.60%), Vanguard Group Inc. (4.81%), StepStone Group LP (2.04%), State Street Corp (1.22%) and Peregrine Capital Management LLC (0.96%). Company insiders that own NovoCure Limited stock include Asaf Danziger, Eilon D Kirson, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Robert J Mylod Jr and Yoram Palti. View Institutional Ownership Trends for NovoCure Limited.

Who sold NovoCure Limited stock? Who is selling NovoCure Limited stock?

NovoCure Limited's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Macquarie Group Ltd., Wedbush Securities Inc., ProShare Advisors LLC and SG Americas Securities LLC. Company insiders that have sold NovoCure Limited stock in the last year include Asaf Danziger, Eilon D Kirson, Michael J Ambrogi, Pomona Capital Vii Fund Invest and Yoram Palti. View Insider Buying and Selling for NovoCure Limited.

Who bought NovoCure Limited stock? Who is buying NovoCure Limited stock?

NovoCure Limited's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., FMR LLC, Vanguard Group Inc., Frontier Capital Management Co. LLC, PointState Capital LP, C WorldWide Group Holding A S, State Street Corp and Engineers Gate Manager LP. Company insiders that have bought NovoCure Limited stock in the last two years include Asaf Danziger, Gert L Perlhagen and Robert J Mylod Jr. View Insider Buying and Selling for NovoCure Limited.

How do I buy NovoCure Limited stock?

Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovoCure Limited's stock price today?

One share of NovoCure Limited stock can currently be purchased for approximately $21.05.

MarketBeat Community Rating for NovoCure Limited (NASDAQ NVCR)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about NovoCure Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NovoCure Limited (NASDAQ:NVCR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $20.14 (4.31% downside)

Analysts' Ratings History for NovoCure Limited (NASDAQ:NVCR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017MizuhoInitiated CoverageBuy$25.00MediumView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingHold$18.00 -> $19.00LowView Rating Details
5/24/2017Wells Fargo & CompanyUpgradeMarket Perform -> Outperform$15.00HighView Rating Details
5/1/2017J P Morgan Chase & CoReiterated RatingBuy$14.00HighView Rating Details
4/27/2017WedbushReiterated RatingOutperform$20.00LowView Rating Details
4/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
4/4/2017JMP SecuritiesReiterated RatingOutperform$34.00HighView Rating Details
7/29/2016Barclays PLCLower Price TargetUnderweight$12.00 -> $9.00N/AView Rating Details
11/12/2015Evercore ISIInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for NovoCure Limited (NASDAQ:NVCR)
Earnings by Quarter for NovoCure Limited (NASDAQ:NVCR)
Earnings History by Quarter for NovoCure Limited (NASDAQ NVCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.15)N/AView Earnings Details
7/27/20176/30/2017($0.23)($0.24)$42.20 million$38.38 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.25)($0.21)$39.46 million$34.88 millionViewN/AView Earnings Details
2/23/2017Q416($0.39)($0.26)$26.95 million$30.20 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.39)$21.65 million$21.67 millionViewN/AView Earnings Details
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
10/26/2015Q315($2.09)$4.37 million$8.95 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NovoCure Limited (NASDAQ:NVCR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for NovoCure Limited (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NovoCure Limited (NASDAQ:NVCR)
Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 36.84%
Insider Trades by Quarter for NovoCure Limited (NASDAQ:NVCR)
Institutional Ownership by Quarter for NovoCure Limited (NASDAQ:NVCR)
Insider Trades by Quarter for NovoCure Limited (NASDAQ:NVCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Asaf DanzigerCEOSell37,272$22.01$820,356.72View SEC Filing  
9/13/2017Asaf DanzigerCEOSell35,500$22.01$781,355.00View SEC Filing  
7/11/2017Asaf DanzigerCEOSell7,383$19.95$147,290.85View SEC Filing  
7/10/2017Asaf DanzigerCEOSell274,359$18.07$4,957,667.13View SEC Filing  
7/6/2017Asaf DanzigerCEOSell160,138$18.14$2,904,903.32View SEC Filing  
7/5/2017Asaf DanzigerCEOSell155,088$18.14$2,813,296.32View SEC Filing  
6/26/2017Pomona Capital Vii Fund InvestMajor ShareholderSell1,072,532$17.35$18,608,430.20View SEC Filing  
6/21/2017Eilon D KirsonInsiderSell66,361$16.78$1,113,537.58View SEC Filing  
6/19/2017Asaf DanzigerCEOSell124,720$15.51$1,934,407.20View SEC Filing  
6/19/2017Eilon D KirsonInsiderSell15,000$15.06$225,900.00View SEC Filing  
6/16/2017Asaf DanzigerCEOSell42,457$15.15$643,223.55View SEC Filing  
6/14/2017Asaf DanzigerCEOSell94,102$15.22$1,432,232.44View SEC Filing  
6/12/2017Asaf DanzigerCEOSell180,601$15.13$2,732,493.13View SEC Filing  
6/12/2017Eilon D KirsonInsiderSell20,956$15.03$314,968.68View SEC Filing  
6/5/2017Yoram PaltiInsiderSell3,825$13.82$52,861.50View SEC Filing  
6/2/2017Yoram PaltiInsiderSell8,000$13.27$106,160.00View SEC Filing  
5/31/2017Yoram PaltiInsiderSell8,000$12.49$99,920.00View SEC Filing  
5/26/2017Yoram PaltiInsiderSell8,000$12.88$103,040.00View SEC Filing  
5/24/2017Yoram PaltiInsiderSell4,000$13.15$52,600.00View SEC Filing  
5/23/2017Yoram PaltiInsiderSell8,000$11.73$93,840.00View SEC Filing  
5/19/2017Yoram PaltiInsiderSell8,000$11.39$91,120.00View SEC Filing  
5/17/2017Yoram PaltiInsiderSell4,000$11.47$45,880.00View SEC Filing  
5/16/2017Yoram PaltiInsiderSell8,000$12.05$96,400.00View SEC Filing  
5/12/2017Yoram PaltiInsiderSell8,000$11.79$94,320.00View SEC Filing  
5/10/2017Yoram PaltiInsiderSell8,000$12.29$98,320.00View SEC Filing  
5/8/2017Yoram PaltiInsiderSell8,000$11.82$94,560.00View SEC Filing  
5/4/2017Yoram PaltiInsiderSell8,000$11.42$91,360.00View SEC Filing  
5/2/2017Yoram PaltiInsiderSell8,000$11.64$93,120.00View SEC Filing  
4/28/2017Yoram PaltiInsiderSell8,000$11.25$90,000.00View SEC Filing  
4/26/2017Yoram PaltiInsiderSell8,000$10.78$86,240.00View SEC Filing  
4/24/2017Yoram PaltiInsiderSell8,000$11.26$90,080.00View SEC Filing  
4/20/2017Yoram PaltiInsiderSell8,000$11.24$89,920.00View SEC Filing  
4/18/2017Yoram PaltiInsiderSell16,000$10.64$170,240.00View SEC Filing  
4/17/2017Yoram PaltiCTOSell4,000$10.77$43,080.00View SEC Filing  
4/13/2017Yoram PaltiCTOSell4,000$10.43$41,720.00View SEC Filing  
4/12/2017Yoram PaltiCTOSell4,000$10.72$42,880.00View SEC Filing  
3/14/2017Gert L PerlhagenDirectorBuy125,000$6.93$866,250.00View SEC Filing  
12/22/2016Michael J AmbrogiCOOSell27,500$8.27$227,425.00View SEC Filing  
12/20/2016Michael J AmbrogiCOOSell20,000$8.62$172,400.00View SEC Filing  
12/19/2016Michael J AmbrogiCOOSell20,000$8.76$175,200.00View SEC Filing  
12/16/2016Michael J AmbrogiCOOSell40,000$8.93$357,200.00View SEC Filing  
12/14/2016Michael J AmbrogiCOOSell40,000$8.97$358,800.00View SEC Filing  
12/12/2016Michael J AmbrogiCOOSell15,000$9.01$135,150.00View SEC Filing  
12/8/2016Michael J AmbrogiCOOSell10,000$8.30$83,000.00View SEC Filing  
12/6/2016Michael J AmbrogiCOOSell10,000$8.24$82,400.00View SEC Filing  
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NovoCure Limited (NASDAQ:NVCR)
Latest Headlines for NovoCure Limited (NASDAQ:NVCR)
DateHeadline logo$43.26 Million in Sales Expected for NovoCure Limited (NVCR) This Quarter - September 17 at 12:02 PM logoAnalyzing ZIOPHARM Oncology (ZIOP) and NovoCure Limited (NVCR) - September 16 at 10:48 AM logoNovoCure Limited (NVCR) CEO Asaf Danziger Sells 35,500 Shares - September 15 at 7:44 PM logoNovoCure Limited (NVCR) CEO Asaf Danziger Sells 37,272 Shares - September 15 at 7:24 PM logoNovoCure Reaches Analyst Target Price - September 15 at 6:56 AM logoAnalyzing NovoCure Limited (NVCR) and The Competition - September 14 at 4:18 AM logoNovoCure Limited (NVCR) Receives Consensus Recommendation of "Buy" from Analysts - September 9 at 9:08 AM logoNovocure Announces Data Presentations at the ESMO 2017 Congress - September 7 at 7:02 AM logoNovoCure Limited (NVCR) Research Coverage Started at Mizuho - September 6 at 5:52 PM logoGerman Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma - September 6 at 7:00 AM logoNovoCure Limited (NVCR) Expected to Post Quarterly Sales of $43.26 Million - August 29 at 4:54 AM logoNovoCure Limited (NVCR) Expected to Announce Earnings of -$0.21 Per Share - August 27 at 4:14 PM logoNovocure to Present at Two Upcoming Investor Conferences in September - August 24 at 10:25 AM logoNovoCure Limited (NVCR) Receives Average Recommendation of "Buy" from Analysts - August 15 at 11:56 AM logoETFs with exposure to Novocure Ltd. : August 11, 2017 - August 12 at 6:25 AM logoETFs with exposure to Novocure Ltd. : August 11, 2017 - August 12 at 6:25 AM logo Analysts Expect NovoCure Limited (NVCR) Will Post Quarterly Sales of $43.26 Million - August 11 at 4:04 PM logo3 Earnings Movers Among Our 4 Charts To Watch - August 10 at 6:22 AM logoNovocure™ Announces National Reimbursement for Optune® in Austria - August 9 at 5:35 AM logoNovocure to Present at the 2017 Wedbush PacGrow Healthcare Conference - August 3 at 6:28 AM logo3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment - August 3 at 6:28 AM logoNovocure Ltd. :NVCR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 - July 29 at 5:43 AM logoNovocure Reports Second Quarter 2017 Financial Results and Provides Company Update - July 28 at 6:17 AM logoInvestor Network: Novocure Ltd. to Host Earnings Call - July 28 at 6:17 AM logoEdited Transcript of NVCR earnings conference call or presentation 27-Jul-17 12:00pm GMT - July 28 at 6:17 AM logoNovoCure reports 2Q loss - July 28 at 6:17 AM logoNovoCure Limited (NASDAQ:NVCR) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS - July 27 at 2:18 PM logoCommit To Buy NovoCure At $15, Earn 19.7% Annualized Using Options - Nasdaq - July 27 at 5:35 AM logoNovocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma - July 24 at 8:57 AM logoNovoCure Limited (NASDAQ:NVCR) Expected to Post Quarterly Sales of $42.20 Million - July 22 at 12:20 PM logoMany treatment options, most experimental, available to John McCain - July 22 at 7:07 AM logoNovoCure Limited (NVCR) Given Average Rating of "Buy" by Analysts - July 21 at 9:12 AM logo Brokerages Anticipate NovoCure Limited (NVCR) to Announce -$0.21 EPS - July 20 at 9:15 AM logoNovocure Ltd (NVCR) Price Target Raised to $19.00 at Deutsche Bank AG - July 17 at 7:14 PM logoToday's Research Report Coverage on Medical Equipment Stocks -- NovoCure, Corindus Vascular Robotics ... - PR Newswire (press release) - July 17 at 9:25 AM logoNovoCure Limited (NVCR) CEO Asaf Danziger Sells 7,383 Shares - July 13 at 8:17 PM logoNovoCure (NVCR) Jumps: Stock Rises 10.5% - Nasdaq - July 13 at 7:27 AM logoNovocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S. - July 13 at 7:27 AM logoToday's Research Reports on Stocks to Watch: Amicus Therapeutics, Inc. and NovoCure Ltd. - July 13 at 7:27 AM logoNovoCure (NVCR) Jumps: Stock Rises 10.5% - July 13 at 7:27 AM logoThe Fastest Growing Cancer Company You've Never Heard Of - July 13 at 7:27 AM logoData on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society - July 12 at 6:29 AM logoNovoCure Limited (NVCR) CEO Sells $4,957,667.13 in Stock - July 11 at 7:53 PM logoNovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger Sells 155,088 Shares - July 7 at 7:58 PM logoAsaf Danziger Sells 160,138 Shares of NovoCure Limited (NVCR) Stock - July 7 at 7:56 PM logoZacks Investment Research Downgrades NovoCure Limited (NASDAQ:NVCR) to Sell - July 3 at 9:32 PM logoNovoCure Limited (NASDAQ:NVCR) Upgraded to Buy at Zacks Investment Research - July 2 at 7:28 AM logoIs NovoCure (NVCR) a Great Growth Stock? - Nasdaq - July 1 at 5:49 AM logoNovocure to Report Second Quarter 2017 Financial Results - July 1 at 5:49 AM logoIs NovoCure (NVCR) a Great Growth Stock? - July 1 at 5:49 AM



NovoCure Limited (NVCR) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff